KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Accumulated Expenses (2016 - 2025)

Neogenomics (NEO) has disclosed Accumulated Expenses for 16 consecutive years, with $47.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 276.9% year-over-year to $47.6 million, compared with a TTM value of $47.6 million through Dec 2025, up 276.9%, and an annual FY2025 reading of $47.6 million, up 276.9% over the prior year.
  • Accumulated Expenses was $47.6 million for Q4 2025 at Neogenomics, up from $17.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $53.2 million in Q4 2023 and bottomed at $12.6 million in Q4 2024.
  • Average Accumulated Expenses over 5 years is $28.0 million, with a median of $23.3 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses plummeted 76.25% in 2024, then soared 276.9% in 2025.
  • Year by year, Accumulated Expenses stood at $17.8 million in 2021, then skyrocketed by 125.56% to $40.1 million in 2022, then surged by 32.44% to $53.2 million in 2023, then tumbled by 76.25% to $12.6 million in 2024, then skyrocketed by 276.9% to $47.6 million in 2025.
  • Business Quant data shows Accumulated Expenses for NEO at $47.6 million in Q4 2025, $17.4 million in Q3 2025, and $18.5 million in Q2 2025.